A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Last updated: June 16, 2021
Sponsor: Actelion
Overall Status: Terminated

Phase

3

Condition

Stress

Circulation Disorders

Vascular Diseases

Treatment

N/A

Clinical Study ID

NCT03809650
AC-055E301
  • Ages 18-89
  • All Genders

Study Summary

The endothelin receptor antagonist macitentan showed significant improvement compared with placebo in pulmonary vascular resistance (PVR) and 6-minute walking distance (6MWD) in inoperable CTEPH patients in the phase II MERIT-1 trial (AC-055E201, NCT02021292). However, in the MERIT-1 trial Japanese patients were not included. Therefore, in line with Japan's medical environment, this phase III study is to confirm the efficacy and safety of macitentan in Japanese CTEPH patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Written informed consent to participate in the study obtained from the subject orlegal representative a) prior to initiation of any study mandated procedure
  • Japanese subjects who have been diagnosed as having CTEPH:
  1. Subjects who have not undergone balloon pulmonary angioplasty (BPA) and for whomthe investigator determines not to implement pulmonary endarterectomy (PEA) atthe time of the acquisition of informed consent due to the organized thrombosislocalized in the peripheral regions, high risk (complications, old age, etc.) orfor any other reasons.
  2. Subjects who have postoperative persistent or recurrent pulmonary hypertension (PH) after undergoing pulmonary endarterectomy (PEA) and/or BPA.
  • PH subjects whose WHO FC is I to IV
  • 6MWD measured during the screening period ranges from 150 m to 450 m
  • Subjects who meet the following conditions according to the right heartcatheterization (RHC) performed during the screening period or within 8 weeks beforethe acquisition of the informed consent:
  1. Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg
  2. Pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg (if PAWP cannot be measured orthe value of PAWP is not reliable, left ventricular end-diastolic pressure ≤ 13mmHg)
  3. Resting PVR ≥ 400 dyn*sec/cm5
  • Subjects treated with anti-coagulation agents, unfractionated heparin or low molecularweight heparin at least 90 days prior to RHC at baseline
  • Women with childbearing potential with negative serum pregnancy test results and ableto follow the appropriate contraceptive methods from the date of starting the studydrug administration up to 30 days after the discontinuation or completion of the studydrug administration. Fertile male subjects able to use condom during the same period.

Exclusion

Exclusion Criteria:

  • BPA within 90 days prior to undergoing baseline RHC
  • PEA within 180 days prior to undergoing baseline RHC
  • Subjects with unstable pulmonary hemodynamics who have postoperative persistent orrecurrent PH after undergoing PEA and/or BPA
  • Recurrent thromboembolism undergoing treatment with oral anti-coagulation agents
  • Symptomatic acute pulmonary embolism within 180 days prior to the start of study drugadministration
  • Known moderate-to-severe restrictive lung disease or obstructive lung disease or knownsignificant chronic lung disease diagnosed by chest imaging (e.g., interstitial lungdisease, emphysema)
  • Acute myocardial infarction during Screening period
  • Severe liver impairment.
  • Systolic blood pressure (SBP) < 90 mmHg at screening.
  • Any known factor or disease that may interfere with treatment compliance or fullparticipation in the study

Study Design

Total Participants: 9
Study Start date:
January 08, 2019
Estimated Completion Date:
June 29, 2020

Connect with a study center

  • Fukuoka University Nishijin Hospital

    Fukuoka, 814-8522
    Japan

    Site Not Available

  • Fukushima Medical University Hospital

    Fukushima, 960-1247
    Japan

    Site Not Available

  • Kagoshima University Hospital

    Kagoshima, 890-8520
    Japan

    Site Not Available

  • Nara Medical University Hospital

    Kashihara, 634-8522
    Japan

    Site Not Available

  • Kokura Kinen Hospital

    Kitakyushu, 802-8555
    Japan

    Site Not Available

  • Kokura Kinen Hospital

    Kitakyusyu, 802-8555
    Japan

    Site Not Available

  • Kobe University Hospital

    Kobe, 650-0017
    Japan

    Site Not Available

  • Saitama Cardiovascular and Respiratory Center

    Kumagaya, 360-0197
    Japan

    Site Not Available

  • Kure Kyosai Hospital

    Kure, 737-8505
    Japan

    Site Not Available

  • Kurume University Hospital

    Kurume, 830-0011
    Japan

    Site Not Available

  • Toho University Ohashi Medical Center

    Meguro-ku, 153-8515
    Japan

    Site Not Available

  • IIUHW Mita Hospital

    Minato-ku, 108-8329
    Japan

    Site Not Available

  • Kyorin University Hospital

    Mitaka, 181-8611
    Japan

    Site Not Available

  • Nagasaki University Hospital

    Nagasaki, 852-8501
    Japan

    Site Not Available

  • National Hospital Organization Okayama Medical Center

    Okayama, 701-1192
    Japan

    Site Not Available

  • Hokkaido University Hospital

    Sapporo, 060-8648
    Japan

    Site Not Available

  • Sapporo Medical University Hospital

    Sapporo, 060-8543
    Japan

    Site Not Available

  • Sasebo City General Hospital

    Sasebo, 857-8511
    Japan

    Site Not Available

  • Keio University Hospital

    Shinjuku-ku, 160-0016
    Japan

    Site Not Available

  • National Cerebral and Cardiovascular Center Hospital

    Suita, 565-8565
    Japan

    Site Not Available

  • Mie University Hospital

    Tsu, 514-8507
    Japan

    Site Not Available

  • University of Tsukuba Hospital

    Tsukuba, 305-8576
    Japan

    Site Not Available

  • Yamagata University Hospital

    Yamagata, 990-0828
    Japan

    Site Not Available

  • Yokohama City University Hospital

    Yokohama, 236-0004
    Japan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.